Atrium Therapeutics, Inc.
RNA
Rank in Stocks
#18131
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to... Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Share Price
$8.38
Last synced: 2026-11-09
Market Cap
$143.35M
Change (1 day)
0.48%
Change (1 year)
-
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Atrium Therapeutics, Inc. (RNA)
Category
Healthcare
EPS for Atrium Therapeutics, Inc. (RNA)
EPS as of June 2026 TTM: $-3.85
According to Atrium Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-3.85. At the end of 2025 the company had an EPS of $-4.48, a decrease compared to its 2024 EPS of $-2.89.
EPS history for Atrium Therapeutics, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.85 | -14.06% |
| 2025 | $-4.48 | 55.02% |
| 2024 | $-2.89 | -0.69% |
| 2023 | $-2.91 | -12.87% |
| 2022 | $-3.34 | 17.19% |
| 2021 | $-2.85 | 39.02% |
| 2020 | $-2.05 | 138.37% |
| 2019 | $-0.86 | 48.28% |
| 2018 | $-0.58 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -506.75% |
US
|
|
| $-7.07 | 83.64% |
US
|
|
| $-5.29 | 37.40% |
AU
|
|
| $12.88 | -434.55% |
BE
|
|
| $21.56 | -660.00% |
NL
|
Questions about Atrium Therapeutics, Inc.'s earnings per share (EPS)
What is Atrium Therapeutics, Inc.'s earnings per share (EPS)?
Atrium Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-3.85, as of Jun 2026.
What was Atrium Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Atrium Therapeutics, Inc.'s earnings per share (EPS) was $-4.48, compared with $-2.89 in 2024.
How has Atrium Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Atrium Therapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($-2.05) and lowest in 2025 ($-4.48).
How does Atrium Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Atrium Therapeutics, Inc.'s earnings per share (EPS) ($-3.85) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.